Clinical trials: Metastatic or Locally Advanced Unresectable Solid Tumors
- Condition Metastatic or Locally Advanced Unresectable Solid Tumors
- Funder type Industry (pharma, biotech, devices)
Solid Tumours
A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors
A Phase 1, Open-Label Study of the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP601 in Patients with Solid Tumours.The study is designed to find the highest dose of AP601 that can be given…
- Trial name
- NCT07165067
- Testing
- AP601
- Where
- 3 sites in Australia
- Volunteers
- 36 people
- Sponsor
- AP Biosciences Inc.
FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma)…
- Trial name
- ReFocus202 (NCT07359820)
- Testing
- Lirafugratinib
- Where
- 19 sites in United States, France and 3 more
- Volunteers
- 30 people
- Sponsor
- Elevar Therapeutics
Locally Advanced Unresectable or Metastatic Solid Tumor
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors
This is a multicenter, open-label, phase I study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic(PD) characteristics of SIM0237 in participants with advanced solid tumors.
- Trial name
- NCT05781360
- Testing
- SIM0237
- Where
- 9 sites in United States, China
- Volunteers
- 192 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced Cancer
Safety Study of FP-1039 To Treat Cancer
The primary purpose of this study is to evaluate the safety and tolerability of FP-1039, a new biologic treatment for cancer.
- Trial name
- NCT00687505
- Testing
- FP-1039
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Five Prime Therapeutics, Inc.
Metastatic or Locally Advanced Unresectable Solid Tumors
First-in-Human Study of MS201408-0005A as Single Agent and in Combinations
This is a Phase I, open-label study to determine the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD), and preliminary antitumor activity of MS201408-0005A as single agent (Part IA only) and in combination with…
- Trial name
- NCT03306420
- Testing
- M4112
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Unresectable or Metastatic Solid Tumors
INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of…
- Trial name
- NCT03589651
- Testing
- Retifanlimab, Epacadostat, INCB050465
- Where
- 9 sites in United States
- Volunteers
- 83 people
- Sponsor
- Incyte Corporation
Solid Tumors
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.
- Trial name
- NCT06963281
- Testing
- IBI3020
- Where
- 9 sites in United States, China
- Volunteers
- 285 people
- Sponsor
- Fortvita Biologics (USA)Inc.
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and carboplatin in patients receiving first- or…
- Trial name
- PRESERVE 2 (NCT04799249)
- Testing
- Trilaciclib, Gemcitabine, Carboplatin
- Where
- 71 sites in United States, Australia and 9 more
- Volunteers
- 194 people
- Sponsor
- G1 Therapeutics, Inc.
Solid Tumor
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
To evaluate the safety and tolerability of IBI3005 combination therapy in participants with advanced solid tumors; to evaluate the antitumor activity of IBI3005 combination therapy in participants with advanced solid tumors.
- Trial name
- NCT07612137
- Testing
- IBI3005, Sintilimab, Bevacizumab biosimilar
- Where
- China
- Volunteers
- 282 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Unresectable Locally Advanced or Metastatic Solid Tumors
IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
This is a phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3014 in participants with unresectable locally advanced or metastatic solid tumors.
- Trial name
- NCT06974812
- Testing
- IBI3014
- Where
- 3 sites in China
- Volunteers
- 250 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumor
A Study of FG-B901 Monotherapy or Combination With Chemotherapy in Advanced or Metastatic Solid Tumors
FG-B901 is a recombinant humanized IgG2 bispecific antibody targeting PD-L1 and CD40. It is designed to provide PD-L1-dependent CD40 agonism, thereby enhancing selectivity for the tumor microenvironment and reducing systemic…
- Trial name
- NCT07623707
- Testing
- FG-B901, standard or investigator-determined chemotherapy
- Where
- China
- Volunteers
- 264 people
- Sponsor
- FutureGen Biopharmaceutical (Beijing) Co., Ltd
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors.
- Trial name
- NCT07488676
- Testing
- ASP546C
- Where
- 21 sites in United States, Japan
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Advanced Solid Tumor
A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
In Phase I, This study will explore the tolerability and safety of RC118 in patients with locally advanced unresectable or metastatic malignant solid tumors with positive Claudin 18.2 expression, and determine the maximum…
- Trial name
- NCT05205850
- Testing
- RC118-ADC
- Where
- 2 sites in China
- Volunteers
- 135 people
- Sponsor
- RemeGen Co., Ltd.
Solid Tumor
HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors
A phase Ib, dose escalation, multiple dose trial with HuMax-IL8 in patients with metastatic or unresectable, locally advanced malignant solid tumors.
- Trial name
- NCT02536469
- Testing
- HuMax-IL8
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor
A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI130. It includes a phase 1 dose escalation and expansion section to identify MTD/RP2D of IBI130, plan to enroll 20~182 subjects,and a phase 2 to explore…
- Trial name
- NCT05923008
- Testing
- IBI130
- Where
- Australia
- Volunteers
- 182 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Metastatic Cancer, Solid Tumor
Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
This is the first study to test Sym022 in humans. The primary purpose of this study is to see if Sym022 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas…
- Conditions
- Metastatic Cancer, Solid Tumor, Lymphoma
- Trial name
- NCT03489369
- Testing
- Sym022
- Where
- 3 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- Symphogen A/S
MSI-H/dMMR Solid Tumor
A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors
It is a single-arm, open-label, multicenter, phase II study to evaluate the safety, efficacy, pharmacokinetics (PK) and immunogenicity of AK104 as a single agent in subjects with previously-treated locally advanced unresectable…
- Trial name
- NCT04547101
- Testing
- AK104
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Akeso
Ovarian Cancer, Small Cell Lung Cancer
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C…
- Conditions
- Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT07752875
- Testing
- LG00313112
- Volunteers
- 250 people
- Sponsor
- LG Chem
Metastatic Cancer, Solid Tumor
Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
The primary purpose of this study is to see if Sym021 is safe and tolerable as monotherapy, in combination with either Sym022 or Sym023, and in Combination with both Sym022 and Sym023 for patients with locally…
- Conditions
- Metastatic Cancer, Solid Tumor, Lymphoma
- Trial name
- NCT03311412
- Testing
- Sym021, Sym022, Sym023
- Where
- 4 sites in United States, Canada
- Volunteers
- 89 people
- Sponsor
- Symphogen A/S
Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT07066657
- Testing
- MRG007, MRG007 and Bevacizumab
- Where
- 21 sites in United States, China
- Volunteers
- 572 people
- Sponsor
- ArriVent BioPharma, Inc.